TrialLeukemia2018

Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.

Sara Bringhen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.